EU regulators back Lilly’s blockbuster RA pill
Pill could generate $2 billion sales.
X
EU regulators back Lilly’s blockbuster RA pill
https://pharmaphorum.com/news/eu-regulators-back-lillys-blockbuster-ra-pill/
Rheumatoid arthritis
Ablynx in talks with partners for RA drug
Biotech suffered setback after AbbVie decided against partnership.
Sanofi/Regeneron RA drug rejected in US
FDA has concerns over Sanofi manufacturing plant.
J&J says ready to fend off Remicade competitor
Pfizer’s rival launch should be considered “at risk”, says J&J
Pfizer set for US launch of Remicade biosimilar
Pfizer gearing up for US launch late next month.
GSK/Janssen’s rheumatoid arthritis drug filed in EU
Drug could compete against Sanofi rival if approved.
Sandoz’s Enbrel biosimilar approved in US
FDA approves first near-copy of inflammatory diseases drug.
Novartis’ Enbrel biosimilar closer to market
FDA committee recommends near-copy.